Prevalence of joint disease in patients with psoriasis: Implications for therapy

American Journal of Clinical Dermatology

Volumn 4, Issue 7, 2003, Pages 441-447

  Zachariae, Hugh ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; ETANERCEPT; GOLD DERIVATIVE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PSORALEN; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTHROPATHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; INFLAMMATION; LIVER TOXICITY; LONG TERM CARE; NEPHROTOXICITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; TISSUE SPECIFICITY;

EID: 0038104272     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304070-00001     Document Type: Review

References (45)

1. Alibert JL. Précis theorique et practique sur les maladies de la peau. Paris: Caille et Ravier, 1818
2. Cats A. Psoriasis and arthritis. In: Farber EM, Cox A, editors. Psoriasis. Proceedings of the 1st International Symposium. Stanford: Stanford University Press, 1971
3. Kremer J, Alarcón G, Lightfoot R, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28
4. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78
5. Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973; 32: 181-201
6. Zachariae E, Zachariae H. Psoriatic Arthritis. In: Roenigk H, Maibach H, editors. Psoriasis. New York: Marcel Decker, 1998
7. Zachariae H, Petersen HO, Kismeyer-Nielsen F, et al. HLA-antigens in pustular psoriasis. Ann Clin Res 1977; 154: 73-7
8. Yates VM, Watkinson G, Kelman A. Further evidence for association between psoriasis, Crohn's disease, and ulcerative colitis. Br J Dermatol 1982; 106: 323-30
9. Hellgren L. Association between rheumatoid arthritis and psoriasis in total populations. Acta Rheum Scand 1969; 15: 316-26
10. Jurik AG, Helmig O, Graudal H. Skeletal disease, arthro-osteitis in adult patients with pustulosis palmoplantaris. Scand J Rheumatol Suppl 1988; 70: 3-15
11. Kahn MF, Kahn MA. The SAPHO syndrome. Baillieres's Clin Rheumatol 1994; 8: 330-83
12. Lambert JR, Ansell BM, Stephenson E, et al. Psoriatic arthritis in childhood. Clin Rheum Dis 1976; 2: 339-52
13. Leonard D, O'Duffy J, Rogers R. Prospective analyses of arthritis in patients hospitalised for psoriasis. Mayo Clin Proc 1978; 53: 511-8
14. Franssen MJ, van den Hoogen FH, Van de Putte LB. Psoriatic arthropathy. In: van de Kerkhof P. editor. Textbook of psoriasis. Oxford: Blackwell Science, 1999
15. Bennet R. Psoriatic arthritis. In: McCarthy DJ, Koopman WJ, editors. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993
16. Zanolli MD, Wikle JS. Joint complaints in psoriasis patients. Int J Dermatol 1992; 31: 488-91
17. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations: data from the Nordic quality of life study. Acta Derm Venereol 2002; 82: 108-13
18. Veys EM, Mielants H. Current concepts in psoriatic arthritis. Dermatology 1994; 189 Suppl. 2: 35-41
19. Lambert JR, Wright V, Rajah SM, et al. Histocompatibility antigens in psoriatic arthritis. Ann Rheum Dis 1976; 35: 526-30
20. Christophers E, Henseler T. Psoriasis type I and type II as subtypes of nonpustular psoriasis. In: Roenigk H, Maibach H, editors. Psoriasis. New York: Marcel Decker. 1991
21. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis. Arch Dermatol 2002; 138: 657-63
22. Espinoza L, Espinoza C, Cuellar M, et al. Fibroblast function in psoriatic arthritis. J Rheumatol 1994; 21: 1502-11
23. Taccari E, Fatorossi A, Moretti S, et al. Phenotypic profile of major synovial cell populations of long-standing psoriatic arthritis. J Rheumatol 1987; 14: 525-30
24. Zachariae H. Methotrexate. In: van de Kerkhof P, editor. Textbook of Psoriasis. Oxford: Blackwell Science, 1999
25. Genestier L. Immunosuppressive properties of methotrexate apoptosis and clonal deletion of activated peripheral T-cells. J Clin Invest 1998; 102: 322-8
26. Cuellar ML, Espinoza LR. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 1997; 23: 797-809
27. Roenigk HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-85
28. Whiting-O'Keefe Q, Fye K, Sach K. Methotrexate and histologic hepatic abnormalities: a metaanalysis. Am J Med 1991; 90: 711-6
29. Lebwohl M, Ellis G, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464-75
30. Zachariae H. Renal toxicity of long-term cyclosporin. Scand J Rheumatol 1999; 28: 65-8
31. Cheregato GC, Leoni A. Treatment of psoriatic arthropathy with etretinate, a two year follow-up. Acta Derm Venereol 1986; 66: 321-4
32. Perlman SG, Gerber LH, Roberts RM, et al. Photo chemotherapy and psoriatic arthritis. Ann Intern Med 1979; 91: 717-22
33. Farr M, Kitas G, Waterhouse L, et al. Sulfalazine in psoriatic arthritis: a doubleblind placebo-controlled study. Br J Rheumatol 1990; 29: 46-9
34. Clegg DO, Reda DJ, Mejlas E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum 1996; 39: 2013-20
35. Feldges DH, Barnes CJ. Treatment of psoriatic arthropathy with either azathioprine or methotrexate. Rheumatol Rehab 1974; 13: 120-4
36. Luzar MJ. Hydroxychloroquine in psoriatic arthropathy: exacerbations of psoriatic skin lesions. J Rheumatol 1982; 9 (3): 462-4
37. Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987; 14 (4): 777-9
38. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002; 138: 686-8
39. Prashant S, West DP, Gordon KB. Biologic therapy for psoriasis, the new therapeutic frontier. Arch Dermatol 2002; 138: 657-63
40. Krueger G. Selective targeting of T cell subsets: focus on alefacept: a remittive therapy for psoriasis. Expert Opin Biol Ther 2002; 2: 431-44
41. Ellis CN, Krueger G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. NEJM 2001; 345: 248-55
42. 1 fusion protein, LFA3TIP) reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis [abstract 233]. Arthritis Rheum 2001; 9 Suppl.: s91
43. Stein C, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The methotrexate-cyclosporine combination study group. Arthritis Rheum 1997, 3
44. Clark C, Kirby B, Morris A, et al. Combination treatment with methotrexate and cyclosporine for severe recalcitrant psoriasis. Br J Dermatol 1999; 141: 279-82
45. Finlay AY, Coles EC. The effects of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44